John E. Bishop, Ph.D. joined Genocea in May 2016 as Executive Vice President of Pharmaceutical Sciences. Prior to joining Genocea, Dr. Bishop was Vice President (2004-2006) and then Senior Vice President (2006-2016) of Pharmaceutical Sciences at Momenta Pharmaceuticals. At Momenta, he was responsible for all aspects of chemistry, manufacturing, and controls (CMC) across an array of novel, generic, and biosimilar products, including the landmark approval and launch of generic versions of the complex products Lovenox® and Copaxone®. Before Momenta, Dr. Bishop spent a combined 13 years in various roles of increasing scope and responsibility at Millennium Pharmaceuticals as CMC Leader of Velcade ®; DuPont Phamaceuticals; and Alcon Laboratories, where he co-invented the anti-glaucoma drug Travatan®. He holds a Ph.D. in Organic Chemistry from the University of California, Berkeley, an M.B.A. from Northeastern University, and a B.S. in Chemistry and German from Tufts University.
William Clark has served as our President and Chief Executive Officer since February 2011. Previously he served as our Chief Business Officer from August 2010 to February 2011. Mr. Clark has served on our board of directors since February 2011. Prior to joining our Company, he served as Chief Business Officer at Vanda Pharmaceuticals, Inc. ("Vanda"), a biopharmaceutical company he co-founded in 2004. While at Vanda, he led the company’s strategic and business development activities, and played a central role in raising more than $220 million in multiple public and private financings. Prior to Vanda, Mr. Clark was a principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies, after serving in a variety of commercial and strategic roles at SmithKline Beecham (now GlaxoSmithKline). Mr. Clark holds a B.A. from Harvard University and an M.B.A. from The Wharton School at the University of Pennsylvania.
Jessica Baker Flechtner, Ph.D. joined Genocea in 2007, soon after the company was founded, and currently serves as the Chief Scientific Officer. Dr. Flechtner is a pioneer in the development of novel vaccines directed toward T cell immunity, and has more than 20 years of experience in immunology, infectious disease, cancer, and vaccine development. She leads Genocea’s efforts to develop T cell-directed vaccines and immunotherapies against infectious diseases and other indications. Prior to joining Genocea, Dr. Flechtner developed vaccines and immunotherapies for cancer, infectious disease, autoimmunity and allergy in several companies including Mojave Therapeutics and Antigenics Inc. (now Agenus). She is an inventor on ten pending and four issued patents and has multiple peer-reviewed scientific publications. Dr. Flechtner performed her post-doctoral work at the Dana Farber Cancer Institute and Harvard Medical School. She holds a Ph.D. in Cellular Immunology and a B.S. in Animal Science from Cornell University, and is a member of the American Association of Immunologists, American Association for Cancer Research, Society for Immunotherapy of Cancer, and American Society for Microbiology.
Seth Hetherington, M.D. has served as our Chief Medical Officer since joining our Company in January 2011. Prior to joining our Company, Dr. Hetherington served as Senior Vice President of Clinical and Regulatory Affairs at Icagen, Inc., or Icagen, from May 2006 through December 2010. Prior to Icagen, Dr. Hetherington served as Vice President, Clinical Development and Chief Medical Officer at Inhibitex Inc. from June 2002 through April 2005 and held various positions of increasing responsibility in clinical drug development at GlaxoSmithKline from 1995 through June 2002. Dr. Hetherington has also served as a faculty member at the University of North Carolina School of Medicine and held appointments at several leading academic medical centers, including the University of Tennessee, St. Jude Children's Research Hospital in Memphis and Albany Medical College. Dr. Hetherington earned his B.S. at Yale University and his M.D. at the University of North Carolina, Chapel Hill. He completed his postgraduate training in pediatrics and pediatric infectious diseases at the University of North Carolina and the University of Minnesota, respectively. Dr. Hetherington has published extensively in medical and scientific literature, and is board certified in both pediatrics and pediatric infectious diseases. He also served as the industry representative to the Vaccines and Related Blood Products Advisory Committee of the FDA. He currently serves as the industry representative on the National Vaccine Advisory Committee of the U.S. Department of Health and Human Services.
Prior to joining Genocea, Eric was vice president of corporate and business development, program management and commercial operations at Idenix Pharmaceuticals, Inc. before its acquisition by Merck in August 2014. Eric also held roles in investor relations and corporate communications whilst at Idenix. Prior to Idenix, Eric spent four years at Biogen Idec in investor relations and business development roles and spent six years on Wall Street as an equity research analyst at J.P. Morgan, Schwab Soundview Capital Markets and Bear Stearns. Before starting on Wall Street in 2001, he was a post-doctoral research scientist in the Department of Immunobiology at Guy's Hospital in London, studying T cell development. He has authored several book chapters and peer-reviewed papers, including in Cell,Immunity, and Genes & Development. He holds a Ph.D. in Immunobiology from Yale University and a B.S. in Biology from Trinity University.
Prior to joining Genocea, Jonathan was Senior Vice President of Finance for Shire plc (NASDAQ: SHPG). During his time at Shire, Jonathan held a number of senior roles in Finance and Strategic Planning and Portfolio Management, including as leader of the finance teams supporting Shire’s Global Business Development, R&D and Technical Operations activities and divisional CFO and head of Strategic Planning and Portfolio Management of Shire HGT, its Rare Disease division. Jonathan began his career in the UK in investment banking with UBS Warburg and ING Barings and also worked as an investment manager for Avanti Capital Plc, a UK private equity investment firm. Jonathan has a MBA from London Business School and a BSc in Biological Sciences from Durham University in the UK.